Consumption and cost of antipsychotic drugs;Consumo y gasto de fármacos antipsicóticos

Actas Espanolas de Psiquiatria

Volumn 33, Issue 2, 2005, Pages 110-116

  Perez J ^a   Marin N ^a   Vallano, A ^a,b   Castells, X ^a   Capella D ^a  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antipsychotic drugs; Cost analysis; Drug consumption; Drug usage study; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIOPROPERAZINE; THIORIDAZINE; TIAPRIDE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DATA BASE; DRUG COST; HUMAN; SCHIZOPHRENIA; SPAIN;

ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; HEALTH CARE COSTS; HUMANS; PREVALENCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SPAIN;

EID: 17844378446     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Eaton WW. The epidemiology of schizophrenia. En: Burrows GD, Norman TR, Rubinstein G, editores. Studies on schizophrenia. Amsterdam: Elsevier, 1986.
2. McGrath J, Emmerson WB. Fortnightly review. Treatment of schizophrenia. BMJ 1999;319:1045-8.
3. Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-49.
4. Wysowski DK, Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry 1989;46:929-32.
5. Schultz S, Andreasen NC. Schizophrenia. Lancet 1999;353:1425-30.
6. Kapur S. Atypical antipsychotics. BMJ 2000;321:1360-1.
7. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. Meta-analysis of randomised controlled trials. Schizophr Res 1999;35:51-68.
8. Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents, Int J Neuropsychopharmacol 2000;3:51-4.
9. Geddes J, Freemantle N, Harrison P, Bebbington B for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
10. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
11. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomised controlled trial. JAMA 2003;290:2693-702.
12. Santamaría B, Pérez M, Montera D, Madurga M, de Abajo J. Use of antipsychotic agents in in Spain through 1985-2000. Eur J Psychiatry 2002;17:471-6.
13. a ed. Oslo, 1998.
14. Instituto Nacional de Estadística. Índice de Precios de Consumo. Qué es y cómo se elabora. Madrid, 1977.
15. a ed. Madrid: McGraw-Hill, 1997.
16. Oydin K, editor. Drug consumption in Norway 1995-1999. Oslo: Nork Medisinaldepot Asa, 2000.
17. National Agency for Medicines. Finnish statistics on medicine, 1998. Helsinki: NAM, 1999.
18. Danish Medicines Agency. Laegemiddelstatistik-den primaere sundehedssektor og sygehussektoten. Disponible en: http: //www.dkma.dk [consulta: 25 julio 2003].
19. Drug use in Iceland 1989-1999. Disponible en http:// brunnur.stjr.is/ interpro/htr.nsppages/lyfjanotkun-1989-1999 [consulta: 25 julio 2003)].
20. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003;37:55-61.
21. Start C, Jones J, Agnew J, Hepburn T. Anti-psychotic drug prescribing trends in primary care in Scotland 1994-1997. Health Bull 2000;58:96-101.
22. Haman J, Ruppert A, Auby P, Pugner K, Kissling W. Antpsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database, Int J Clin Psychopharmacol 2003;18:237-42.
23. Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999;33:896-901.
24. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000;22:195-214.
25. Chakos M, Lieberman J, Huffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analyisis of randomised trials. Am J Psychiatry 2001;158:518-26.
26. De la Mata I, Ortiz A. Sesgos y dificultades en la investigación de los nuevos antipsicóticos. Rev Asoc Esp Neurpsiq 2001;21:57-74.
27. Ganguli R. Weight gain associated with antipsychotics drugs. J Clin Psychiatry 1999;60(Suppl. 21):20-4.
28. Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001;286:1945-8.